Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
Lists
Only you see this
Abstract
Expression of p85 and p110alpha subunits is up-regulated in melanoma, indicating that PI3K is a good drug target. Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition. pS6 should be evaluated as a predictor of response in melanoma patients treated with PI3K inhibitors, as these drugs enter clinical trials.
BibTeX
@inproceedings{aziz2009phosphatidylinositol,
author = {Saadia A. Aziz and Michael A. Davies and Elah Pick and Christopher R. Zito and Lucia B. Jilaveanu and Robert L. Camp and David L. Rimm and Yuval Kluger and Harriet M. Kluger},
title = {{Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma}},
booktitle = {Clinical},
year = {2009},
doi = {10.1158/1078-0432.ccr-08-2768},
}Loading related content...